Although the exact mechanism by which BI-TK/GCV reaches its intracellular targets is unclear, the targeting proteins of BI-TK/GCV are supposed to participate in the proliferation and apoptosis of bladder cancer cells, and provide novel targets for future therapy. This evidence concerns the gene TKT and urinary bladder cancer.